Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipids and AIDS].

J Ducobu1, M C Payen

  • 1Services de Médecine, C.H.U. Tivoli, La Louvière.

Revue Medicale De Bruxelles
|April 5, 2000
PubMed
Summary
This summary is machine-generated.

HIV infection alters lipid levels, increasing triglycerides and decreasing HDL, correlating with disease severity. This dyslipidemia, potentially linked to antiretroviral drugs, elevates cardiovascular risk in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe pulmonary TB rescued with extracorporeal membrane oxygenation therapy.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

TB in the intensive care unit in a low-endemic country.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Tuberculosis and pseudoaneurysms.

Medecine et maladies infectieuses·2020
Same author

Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
Same author

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

Pulmonology·2017
Same author

Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy.

Epidemiology and infection·2017
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Context:

  • HIV infection significantly impacts lipid metabolism.
  • Antiretroviral therapies, particularly protease inhibitors, are associated with lipodystrophy and metabolic syndrome.
  • Cytokines released during HIV infection may contribute to dyslipidemia.

Purpose:

  • To elucidate the mechanisms of dyslipidemia in HIV-infected individuals.
  • To explore the link between HIV, antiretroviral drugs, and metabolic complications.
  • To assess the cardiovascular risk associated with HIV-induced dyslipidemia.

Summary:

  • HIV infection causes early cholesterol decrease and later triglyceride increase, with reduced HDL, proportional to CD4 count decline.
  • Mechanisms include increased TG synthesis, decreased TG catabolism, reduced lipoprotein lipase activity, and enhanced LDL catabolism.

Related Experiment Videos

  • Antiprotease drugs can induce lipodystrophy, central obesity, insulin resistance, and cushingoid features, increasing cardiovascular risk.

    • Impact:

    • Highlights the significant cardiovascular risk in HIV patients due to dyslipidemia.
    • Emphasizes the need to understand the pathogenesis of these metabolic complications.
    • Suggests that managing dyslipidemia in HIV patients requires strategies similar to non-infected individuals, while seeking safer antiretroviral agents.